Who
Jonathan Robert Hunt
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Perspective Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 10
- Sells
- 0
- Bought
- $235K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Oct 2006
- Last trade
- 2 Mar 2026
- Last filed
- 4 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $22K11,000 at $2.03 | filing |
| 3 Mar 2025filed 5 Mar 2025 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 25 Nov 2024filed 27 Nov 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,420400 at $3.55 | filing |
| 25 Nov 2024filed 27 Nov 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $11429 at $3.94 | filing |
| 25 Nov 2024filed 27 Nov 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $8,6402,400 at $3.60 | filing |
| 25 Nov 2024filed 27 Nov 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $39K10,000 at $3.88 | filing |
| 20 Jun 2024filed 24 Jun 2024 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 17 Jun 2024filed 18 Jun 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K1,800 at $9.82 | filing |
| 31 May 2024filed 3 Jun 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $18K13,006 at $1.40 | filing |
| 31 May 2024filed 3 Jun 2024 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $17K12,000 at $1.40 | filing |
| 18 Dec 2023filed 19 Dec 2023 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $33K125,000 at $0.26 | filing |
| 12 Dec 2023filed 14 Dec 2023 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,248,776 at $0.00 | filing |
| 5 Dec 2022filed 5 Dec 2022 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $12K32,200 at $0.38 | filing |
| 1 Dec 2022filed 5 Dec 2022 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K53,204 at $0.38 | filing |
| 21 Jul 2022filed 28 Jul 2022 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —475,000 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $7,44625,675 at $0.29 | filing |
| 7 Jun 2022filed 9 Jun 2022 | CATX Perspective TherapeuticsBiotechnology | SEC FORM 4 Bought | $3,73113,325 at $0.28 | filing |
| 1 Jul 2021filed 6 Jul 2021 | CATX Perspective Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.